A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed/ Refractory Multiple Myeloma

This is a single arm, open-label, dose escalation clinical study to evaluate the safety and tolerability of autologouschimeric antigen receptor T (CAR-T) cells targeting CD19/CD22/BCMA in patients with relapsed/refractory multiple myeloma.

Trial Details

NCT ID
NCT06732232
Phase
EARLY_PHASE1
Sponsor
Shanghai Cell Therapy Group Co.,Ltd
Status
RECRUITING
Cancer Type
Multiple Myeloma
Interventions
  • CD19/CD20/BCMA CAR-T
Locations (sample)
  • Shanghai, China|31.22222,121.45806

Key Eligibility Criteria

  • Participants must meet all of the following criteria in order to be enrolled:
  • Understand and voluntarily sign an informed consent form (ICF) before conducting any research related evaluations/procedures;
  • Age range: 18-75 years old;
  • Expected survival period is not less than 12 weeks;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Multiple Myeloma Trials on Trialify →